Avastin Misses Overall-survival Endpoint In Lung Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Analysts expect minimal damage to sales as a result of AVAiL data.
You may also be interested in...
Avastin Breast Cancer Approval In Spotlight With AVADO
CHICAGO - First placebo-controlled, double-blinded evidence for bevacizumab in first-line metastatic breast cancer presented at ASCO.
Avastin Breast Cancer Approval In Spotlight With AVADO
CHICAGO - First placebo-controlled, double-blinded evidence for bevacizumab in first-line metastatic breast cancer presented at ASCO.
The Endgame on Oncology Endpoints
The annual ASCO meeting, held in Chicago this year, provided a forum for investigators to discuss the merits of continued use of progression-free survival as an endpoint in oncology clinical trials. Phase III data from Roche/Genentech's Avastin in metastatic breast cancer sparked debate.